All In Biotech

Drug Trial Radar · NCT07509242

Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental Study

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Mar 18, 2026

Primary completion

Jan 18, 2027

Study completion Jan 18, 2028

Sponsor

Lead sponsor
Yohanes Firmansyah, dr, MH, MMAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to analyze the effectiveness of SM-hUCMSC secretome administered via microneedling and intradermal microinjection as adjuvant therapy to NB-UVB, compared with NB-UVB alone, in terms of repigmentation, onset of improvement, safety, patient satisfaction, and vitiligo recurrence. The main questions it aims to answer are: * Are there differences in the level of vitiligo lesion repigmentation among the secretome therapy via microneedling, intradermal microinjection, and NB-UVB phototherapy groups? * Are there differences in the time to onset of repigmentation among the treatment groups? What are the safety profiles and adverse events associated with each treatment modality? * Are there differences in patient satisfaction and quality of life after undergoing each therapy? * Are there differences in vitiligo recurrence rates during the follow-up period among the treatment groups? Participants will be allocated into three groups as follows: * Group A receives NB-UVB combined with microneedling and topical 10% secretome. * Group B receives NB-UVB combined with intradermal secretome injection. * Group C receives NB-UVB alone. The intervention period lasts 12 weeks, with follow-up until week 24.

Conditions

  • Vitiligo

Interventions

  • NB-UVB combined with microneedling and topical 10% secretomeOther

    Group A receives NB-UVB combined with microneedling and topical 10% secretome.

  • receives NB-UVB combined with intradermal secretome injectionOther

    Group B receives NB-UVB combined with intradermal secretome injection

  • NB-UVB aloneDrug

    Group C receives NB-UVB alone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Achieving ≥50% Repigmentation Assessed by Vitiligo Area Scoring Index (VASI)Time frame: Baseline, Week 4, Week 8, Week 12 (primary endpoint), and Week 24 (follow-up)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Klinik Precious Me

    Tangerang, Banten, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.